FDA Approved: EXFORGE HCT — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA approved a supplemental application for EXFORGE HCT, a fixed-dose combination antihypertensive (amlodipine/valsartan/hydrochlorothiazide) from Novartis Phar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Exforge HCT (amlodipine/valsartan/hydrochlorothiazide)

Snippet

SUPPL AP for EXFORGE HCT (AMLODIPINE VALSARTAN AND HYDROCHLOROTHIAZIDE)